• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

造血细胞移植和细胞治疗受者 COVID-19 管理指南。

Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.

机构信息

University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center, Seattle, Washington.

University of Colorado Denver, Denver, Colorado.

出版信息

Biol Blood Marrow Transplant. 2020 Nov;26(11):1983-1994. doi: 10.1016/j.bbmt.2020.07.027. Epub 2020 Jul 28.

DOI:10.1016/j.bbmt.2020.07.027
PMID:32736007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7386267/
Abstract

There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.

摘要

目前，关于造血细胞移植和细胞治疗受者中 2019 年冠状病毒病（COVID-19）的流行病学、临床表现和最佳治疗方法的数据有限。鉴于其他呼吸道病毒的经验，我们预计患者可能会出现严重的临床疾病，因此为全国的癌症中心提供以下一般原则。这些指南由美国移植和细胞治疗学会传染病特别兴趣小组的成员制定。具体实践可能因当地的流行病学和检测能力而异，并且随着新信息的出现，本文档中提供的指南可能会发生变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f203/7386267/af670ec91bd5/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f203/7386267/b93e995d2e29/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f203/7386267/af670ec91bd5/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f203/7386267/b93e995d2e29/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f203/7386267/af670ec91bd5/gr2_lrg.jpg

相似文献

1
Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients.造血细胞移植和细胞治疗受者 COVID-19 管理指南。
Biol Blood Marrow Transplant. 2020 Nov;26(11):1983-1994. doi: 10.1016/j.bbmt.2020.07.027. Epub 2020 Jul 28.
2
American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Position Statement on Pharmacy Practice Management and Clinical Management for COVID-19 in Hematopoietic Cell Transplantation and Cellular Therapy Patients in the United States.美国移植与细胞治疗学会药房特别兴趣小组关于美国造血细胞移植和细胞治疗患者 COVID-19 的药房实践管理和临床管理的立场声明。
Biol Blood Marrow Transplant. 2020 Jun;26(6):1043-1049. doi: 10.1016/j.bbmt.2020.04.005. Epub 2020 Apr 17.
3
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.新冠病毒治疗和诊断方法的最新进展。
AAPS J. 2021 Jan 5;23(1):14. doi: 10.1208/s12248-020-00532-2.
4
COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management.COVID-19 大流行：从起源到结局。对病毒发病机制、临床表现、诊断评估和治疗的全面综述。
Infez Med. 2021 Mar 1;29(1):20-36.
5
COVID-19: Transmission, prevention, and potential therapeutic opportunities.新型冠状病毒肺炎：传播、预防和潜在治疗机会。
Clin Chim Acta. 2020 Sep;508:254-266. doi: 10.1016/j.cca.2020.05.044. Epub 2020 May 29.
6
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.新型冠状病毒对造血干细胞移植和嵌合抗原受体 T 细胞治疗受者的影响。
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7. doi: 10.1016/j.jtct.2021.07.005. Epub 2021 Jul 10.
7
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022).《造血细胞移植和细胞治疗受者 2019 冠状病毒病管理修订指南》（2022 年 8 月）。
Transplant Cell Ther. 2022 Dec;28(12):810-821. doi: 10.1016/j.jtct.2022.09.002. Epub 2022 Sep 11.
8
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.作为 COVID-19 疗法的抗病毒单克隆抗体面临的挑战与机遇。
Adv Drug Deliv Rev. 2021 Feb;169:100-117. doi: 10.1016/j.addr.2020.12.004. Epub 2020 Dec 9.
9
2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy.2021 年更新的癌症患者 COVID-19 诊治临床实践指南：基于循证医学的管理建议，涵盖诊断、病毒排出、疫苗接种和治疗。
Eur J Cancer. 2021 Apr;147:154-160. doi: 10.1016/j.ejca.2021.01.033. Epub 2021 Feb 10.
10
Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.目前对恢复期血浆疗法（CPT）作为新型冠状病毒病 2019（COVID-19）治疗潜力的看法：基于近期研究和以往呼吸道大流行的系统评价和荟萃分析。
Rev Med Virol. 2021 Nov;31(6):e2225. doi: 10.1002/rmv.2225. Epub 2021 Feb 23.

引用本文的文献

1
Impact of the COVID-19 outbreak on the field of hematopoietic cell transplantation in the Asia-Pacific region: APBMT Activity Survey 2020/2021.2019冠状病毒病疫情对亚太地区造血细胞移植领域的影响：亚太骨髓移植协作组2020/2021年活动调查
Blood Cell Ther. 2024 Nov 25;7(4):129-137. doi: 10.31547/bct-2024-020.
2
Vaccines for Use in Special Populations: Immunocompromised Hosts.特殊人群适用的疫苗：免疫功能低下宿主
J Infect Dis. 2025 Mar 17;231(3):552-555. doi: 10.1093/infdis/jiae508.
3
Comparison of the Clinical Outcomes Between Early and Delayed Transplantation After SARS-CoV-2 Infection.

本文引用的文献

1
Anakinra for severe forms of COVID-19: a cohort study.阿那白滞素用于重症新型冠状病毒肺炎：一项队列研究。
Lancet Rheumatol. 2020 Jul;2(7):e393-e400. doi: 10.1016/S2665-9913(20)30164-8. Epub 2020 May 29.
2
Infectious Diseases Society of America Guidelines on Infection Prevention for Health Care Personnel Caring for Patients with Suspected or Known COVID-19.美国传染病学会关于照顾疑似或确诊 COVID-19 患者的医护人员感染预防指南。
Clin Infect Dis. 2020 Jul 27. doi: 10.1093/cid/ciaa1063.
3
Dexamethasone in Hospitalized Patients with Covid-19.
新型冠状病毒感染后早期与延迟移植的临床结局比较。
J Korean Med Sci. 2024 Apr 15;39(14):e137. doi: 10.3346/jkms.2024.39.e137.
4
Antibiotic prescribing guideline recommendations in COVID-19: a systematic survey.2019冠状病毒病抗生素处方指南建议：一项系统调查
EClinicalMedicine. 2023 Oct 9;65:102257. doi: 10.1016/j.eclinm.2023.102257. eCollection 2023 Nov.
5
The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021.2020 年至 2021 年期间美国血液系统恶性肿瘤患者的 COVID-19 大流行和当面就诊率中断。
JAMA Netw Open. 2023 Jun 1;6(6):e2316642. doi: 10.1001/jamanetworkopen.2023.16642.
6
Diagnostic and Treatment Obstacles in Acute Myeloid Leukemia: Social, Operational, and Financial.急性髓系白血病的诊断与治疗障碍：社会、运营及财务方面
Oncol Ther. 2023 Jun;11(2):145-152. doi: 10.1007/s40487-023-00229-4. Epub 2023 May 13.
7
Clinical impact of cryopreservation of allogeneic hematopoietic cell grafts during the onset of the COVID-19 pandemic.COVID-19 大流行期间，异基因造血细胞移植物冷冻保存的临床影响。
Blood Adv. 2023 Oct 10;7(19):5982-5993. doi: 10.1182/bloodadvances.2023009786.
8
Perspectives and Challenges of COVID-19 with Obesity-Related Cancers.肥胖相关癌症与COVID-19的前景及挑战
Cancers (Basel). 2023 Mar 15;15(6):1771. doi: 10.3390/cancers15061771.
9
Successful Autologous Bone Marrow Transplantation in Active COVID-19 Patients: Case Report.COVID-19 活动期患者自体骨髓移植成功：病例报告。
Transplant Proc. 2023 Apr;55(3):543-546. doi: 10.1016/j.transproceed.2023.02.032. Epub 2023 Feb 27.
10
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.异基因造血干细胞移植受者中 T 细胞富含输注后供体来源的功能性 SARS-CoV-2 特异性 T 细胞：一项前瞻性观察性研究。
Front Immunol. 2023 Mar 3;14:1114131. doi: 10.3389/fimmu.2023.1114131. eCollection 2023.
地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
4
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
5
Drug-induced Liver Injury in a Patient With Coronavirus Disease 2019: Potential Interaction of Remdesivir With P-Glycoprotein Inhibitors.新型冠状病毒疾病 2019 患者的药物性肝损伤：瑞德西韦与 P-糖蛋白抑制剂的潜在相互作用。
Clin Infect Dis. 2021 Apr 8;72(7):1256-1258. doi: 10.1093/cid/ciaa883.
6
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.托珠单抗治疗 COVID-19 住院患者细胞因子释放综合征：生存和临床结局。
Chest. 2020 Oct;158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006. Epub 2020 Jun 15.
7
Hematopoietic stem cell transplantation from an infected SARS-CoV2 donor sibling.来自感染了新冠病毒的供体同胞的造血干细胞移植。
Bone Marrow Transplant. 2020 Dec;55(12):2359-2360. doi: 10.1038/s41409-020-0969-3. Epub 2020 Jun 11.
8
Early safety indicators of COVID-19 convalescent plasma in 5000 patients.5000 例 COVID-19 恢复期血浆治疗的早期安全性指标。
J Clin Invest. 2020 Sep 1;130(9):4791-4797. doi: 10.1172/JCI140200.
9
Disposition of patients with coronavirus disease 2019 (COVID-19) whose respiratory specimens remain positive for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) by polymerase chain reaction assay (PCR).2019冠状病毒病（COVID-19）患者的处置情况，这些患者的呼吸道标本通过聚合酶链反应检测（PCR）对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）仍呈阳性。
Infect Control Hosp Epidemiol. 2020 Nov;41(11):1326-1327. doi: 10.1017/ice.2020.286. Epub 2020 Jun 10.
10
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.在患有新冠肺炎、急性呼吸窘迫综合征和炎症反应过度的患者中使用高剂量阿那白滞素进行白细胞介素-1阻断：一项回顾性队列研究。
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.